L-MIND R/R DLBCL study: 5-year results

The phase II L-MIND study (NCT02399085), previously reported on the Lymphoma Hub, is an open-label, multi-center study evaluating the safety and efficacy of the human anti-CD19 antibody tafasitamab-cxix in combination with lenalidomide in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received 1–3 prior systemic treatment regimens and are not eligible for high dose chemotherapy with autologous stem-cell transplantation at the time of study commencement.

Five-year follow-up results of the trial show prolonged, durable responses in adult patients with R/R DLBCL treated with tafasitamab-cxix plus lenalidomide followed by tafasitamab-cxix monotherapy. These data were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023.¹

Key data

At data cut-off, 80 patients were evaluable for analysis.

• The overall response rate was 57.5%, with 41.2% of patients achieving a complete response (CR) and 16.2% of patients achieving a partial response (PR).
• Median duration of response was not reached after a median follow up of 44.0 months.
• Median overall survival was 33.5 months and median progression-free survival was 11.6 months.
• Among patients with >60 months of follow-up (n = 21), 14 had received one prior line of therapy (pLoT), and seven patients had received ≥2 pLoT.
• Patients with one pLoT (n = 40) had a higher overall response rate of 67.5% (CR, 52.5%; PR, 15%) compared to 47.5% of patients with two or more pLoT (n = 40; CR, 30%; PR, 17.5%).

No new safety signals were observed, with most adverse events (AEs) being Grade 1–2. Patients experienced a reduced frequency of any-grade and Grade ≥3 AEs during monotherapy. The most common AEs were neutropenia and thrombocytopenia in patients who received combination therapy, and neutropenia and diarrhea in those who received monotherapy.